Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
Go back to Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 59.11 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.11 | 52 Week High | $35.13 | |||
| Open | $59.11 | 52 Week Low | $28.10 | |||
| Day High | $59.49 | P/E | N/A | |||
| Day Low | $58.83 | EPS | $0.00 | |||
| Volume | 1,311,205 | |||||



